BACKGROUND: Bidirectional, collaborative partnerships between academic researchers and practitioners have been a fundamental vehicle to achieve the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) goal of improving outcomes of community-based drug treatment. These partnerships blend clinical perspectives of practitioners and methodological expertise of researchers working together to address clinically meaningful issues through randomized clinical trials conducted in community treatment settings. OBJECTIVES: Bidirectionality is a guiding principle of the CTN, but its operationlization at the practical level in protocol development and implementation has not been articulated. This descriptive article presents the development of one protocol as an example and model of this bidirectional, collaborative, iterative partnership between researchers and practitioners. METHODS: This article illuminates several specific issues encountered while developing STAGE-12, a behavioral intervention to facilitate 12-step mutual support group involvement, as well as the rationale for decisions taken to resolve each. RESULTS: The STAGE-12 protocol was successfully developed through a series of decisions taking into account both design factors and clinical practice needs and realities, thus maintaining a balance between methodological rigor and generalizability. CONCLUSION: The review demonstrates the process by which research and practice have been blended in protocol development, exemplifying the underlying principle of bidirectionality, a key element in the success of the NIDA CTN. SCIENTIFIC SIGNIFICANCE: Bidirectional partnerships as derived in the CTN, employing a hybrid model of efficacy-effectiveness research, are capable of designing and implementing protocols that are both methodologically rigorous and clinically meaningful, thus increasing likelihood of adoption and eventual improvement in public health.
BACKGROUND: Bidirectional, collaborative partnerships between academic researchers and practitioners have been a fundamental vehicle to achieve the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) goal of improving outcomes of community-based drug treatment. These partnerships blend clinical perspectives of practitioners and methodological expertise of researchers working together to address clinically meaningful issues through randomized clinical trials conducted in community treatment settings. OBJECTIVES: Bidirectionality is a guiding principle of the CTN, but its operationlization at the practical level in protocol development and implementation has not been articulated. This descriptive article presents the development of one protocol as an example and model of this bidirectional, collaborative, iterative partnership between researchers and practitioners. METHODS: This article illuminates several specific issues encountered while developing STAGE-12, a behavioral intervention to facilitate 12-step mutual support group involvement, as well as the rationale for decisions taken to resolve each. RESULTS: The STAGE-12 protocol was successfully developed through a series of decisions taking into account both design factors and clinical practice needs and realities, thus maintaining a balance between methodological rigor and generalizability. CONCLUSION: The review demonstrates the process by which research and practice have been blended in protocol development, exemplifying the underlying principle of bidirectionality, a key element in the success of the NIDA CTN. SCIENTIFIC SIGNIFICANCE: Bidirectional partnerships as derived in the CTN, employing a hybrid model of efficacy-effectiveness research, are capable of designing and implementing protocols that are both methodologically rigorous and clinically meaningful, thus increasing likelihood of adoption and eventual improvement in public health.
Authors: Edward V Nunes; Samuel Ball; Robert Booth; Gregory Brigham; Donald A Calsyn; Kathleen Carroll; Daniel J Feaster; Denise Hien; Robert L Hubbard; Walter Ling; Nancy M Petry; John Rotrosen; Jeffrey Selzer; Maxine Stitzer; Susan Tross; Paul Wakim; Theresa Winhusen; George Woody Journal: J Subst Abuse Treat Date: 2010-06
Authors: R D Weiss; M L Griffin; R Gallop; L S Onken; D R Gastfriend; D Daley; P Crits-Christoph; S Bishop; J P Barber Journal: Drug Alcohol Depend Date: 2000-08-01 Impact factor: 4.492
Authors: Theresa M Winhusen; Eugene C Somoza; Daniel F Lewis; Frankie B Kropp; Viviana Elizabeth Horigian; Bryon Adinoff Journal: Drug Alcohol Depend Date: 2012-07-06 Impact factor: 4.492
Authors: Elizabeth A Wells; Dennis M Donovan; Dennis C Daley; Suzanne R Doyle; Greg Brigham; Sharon B Garrett; Michelle H Ingalsbe; Mary A Hatch-Maillette; Harold I Perl; Robrina Walker Journal: J Subst Abuse Treat Date: 2014-06-14
Authors: Mary A Hatch-Maillette; Robin Harwick; John S Baer; Tatiana Masters; Kasie Cloud; Michelle Peavy; Katharina Wiest; Lynette Wright; Blair Beadnell; Elizabeth A Wells Journal: Subst Abus Date: 2019-03-04 Impact factor: 3.716
Authors: Dennis M Donovan; Dennis C Daley; Gregory S Brigham; Candace C Hodgkins; Harold I Perl; Sharon B Garrett; Suzanne R Doyle; Anthony S Floyd; Patricia C Knox; Christopher Botero; Thomas M Kelly; Therese K Killeen; Carole Hayes; Nicole Kau'i Baumhofer; Nicole Kau'ibaumhofer; Cindy Seamans; Lucy Zammarelli Journal: J Subst Abuse Treat Date: 2012-05-31
Authors: Joseph Guydish; Barbara K Campbell; Jennifer K Manuel; Kevin L Delucchi; Thao Le; K Michelle Peavy; Dennis McCarty Journal: Drug Alcohol Depend Date: 2013-11-04 Impact factor: 4.492
Authors: Bryon Adinoff; Thomas J Carmody; Robrina Walker; Dennis M Donovan; Gregory S Brigham; Theresa M Winhusen Journal: Am J Drug Alcohol Abuse Date: 2016-01-08 Impact factor: 3.829